{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:26:52Z","timestamp":1782458812323,"version":"3.54.5"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.jacl.2014.02.010","type":"journal-article","created":{"date-parts":[[2014,4,29]],"date-time":"2014-04-29T04:16:57Z","timestamp":1398745017000},"page":"S30-S46","source":"Crossref","is-referenced-by-count":137,"special_numbering":"S","title":["A clinician's guide to statin drug-drug interactions"],"prefix":"10.1016","volume":"8","author":[{"given":"Kenneth A.","family":"Kellick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bottorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2014.02.010_bib1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1124\/pr.111.004994","article-title":"Pharmacological actions of statins: a critical appraisal in the management of cancer","volume":"64","author":"Gazzerro","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jacl.2014.02.010_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake","volume":"63","author":"Niemi","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jacl.2014.02.010_bib3","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2217\/clp.11.57","article-title":"Avoiding statin myopathy: understanding key drug interactions","volume":"6","author":"Harper","year":"2011","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.jacl.2014.02.010_bib4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jacl.2014.02.010_bib5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/clpt.2009.197","article-title":"Transporter pharmacogenetics and statin toxicity","volume":"87","author":"Niemi","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacl.2014.02.010_bib6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","article-title":"Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism","volume":"8","author":"Golomb","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacl.2014.02.010_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/2042098611428486","article-title":"Statins and their interactions with other lipid-modifying medications","volume":"3","author":"Ho","year":"2012","journal-title":"Ther Adv in Drug Safe"},{"key":"10.1016\/j.jacl.2014.02.010_bib8","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/clpt.2012.163","article-title":"Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1","volume":"92","author":"Elsby","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacl.2014.02.010_bib9","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1592\/phco.26.11.1601","article-title":"Role of P-glycoprotein in statin drug interactions","volume":"26","author":"Holtzman","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jacl.2014.02.010_bib10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2013a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2014.02.010_bib11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacl.2014.02.010_bib12","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2014.02.010_bib13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0163-7258(99)00045-5","article-title":"New insights into the pharmacodynamic and pharmacokinetic properties of statins","volume":"84","author":"Corsini","year":"1999","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jacl.2014.02.010_bib14","doi-asserted-by":"crossref","first-page":"77C","DOI":"10.1016\/j.amjcard.2005.12.014","article-title":"National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists","volume":"97","author":"Cohen","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2014.02.010_bib15","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1001\/jama.291.23.2821","article-title":"Pharmacogenetic study of statin therapy and cholesterol reduction","volume":"291","author":"Chasman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2014.02.010_bib16","doi-asserted-by":"crossref","first-page":"III50","DOI":"10.1161\/01.CIR.0000131519.15067.1f","article-title":"Safety of statins: focus on clinical pharmacokinetics and drug interactions","volume":"109","author":"Bellosta","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2014.02.010_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/187231207779814247","article-title":"Prioritization of clinical drug interaction studies using in\u00a0vitro cytochrome P450 data: proposed refinement and expansion of the \u201crank order\u201d approach","volume":"1","author":"Rodriques","year":"2007","journal-title":"Drug Metabolism Letters"},{"key":"10.1016\/j.jacl.2014.02.010_bib18","unstructured":"US Food and Drug Administration. FDA Online Label Repository. Available at: http:\/\/labels.fda.gov\/. Accessed February 9,\u00a02014."},{"key":"10.1016\/j.jacl.2014.02.010_bib19","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm256581.htm. Accessed February 8,\u00a02014."},{"key":"10.1016\/j.jacl.2014.02.010_bib20","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: Revised dose limitation for Zocor (simvastatin) when taken with amiodarone. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm283137.htm. Accessed February 8,\u00a02014."},{"key":"10.1016\/j.jacl.2014.02.010_bib21","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA announces safety changes in labeling for some cholesterol-lowering drugs. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm293101.htm. Accessed February 8,\u00a02014."},{"key":"10.1016\/j.jacl.2014.02.010_bib22","unstructured":"Merck & Co. Inc. ZOCOR (simvastatin) tablets prescribing information. Available at: http:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zocor\/zocor_pi.pdf. Accessed February 8,\u00a02014."},{"key":"10.1016\/j.jacl.2014.02.010_bib23","unstructured":"Parke-Davis-Pfizer. Lipitor (atorvastatin calcium) tablets for oral administration prescribing information. Available at: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=587. Accessed February 8,\u00a02014."},{"key":"10.1016\/j.jacl.2014.02.010_bib24","unstructured":"AstraZeneca. Crestor (rosuvastatin calcium) tablets prescribing information. Available at: http:\/\/www1.astrazeneca-us.com\/pi\/crestor.pdf. Accessed February 8,\u00a02014."},{"key":"10.1016\/j.jacl.2014.02.010_bib25","unstructured":"Kowa Pharmaceuticals America I. LIVALO (pitavastatin) tablet 1 mg, 2 mg, and 4 mg package insert - product labeling. Available at: http:\/\/www.kowapharma.com\/documents\/LIVALO_PI_CURRENT.pdf. Accessed February 8,\u00a02014."},{"key":"10.1016\/j.jacl.2014.02.010_bib26","unstructured":"Merck & Co. Inc. MEVACOR (lovastatin) tablets. Available at: http:\/\/www.merck.com\/product\/usa\/pi_circulars\/m\/mevacor\/mevacor_pi.pdf. Accessed February 9,\u00a02014."},{"key":"10.1016\/j.jacl.2014.02.010_bib27","unstructured":"Novartis Pharmaceuticals Corporation. Lescol (fluvastatin sodium) capsules\/Lescol XL (fluvastatin sodium) extended-release tablets for oral use prescribing information. Available at: https:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/Lescol.pdf. Accessed February 9,\u00a02014."},{"key":"10.1016\/j.jacl.2014.02.010_bib28","unstructured":"Company B-MS. PRAVACHOL (pravastatin sodium) tablets. Available at: http:\/\/packageinserts.bms.com\/pi\/pi_pravachol.pdf. Accessed February 9,\u00a02014."},{"key":"10.1016\/j.jacl.2014.02.010_bib29","unstructured":"Elsevier\/Gold Standard Inc. Clinical Pharmacology [database online]. Available at: http:\/\/www.goldstandard.com\/product\/gold-standard-drug-database. Accessed November,\u00a02013."},{"key":"10.1016\/j.jacl.2014.02.010_bib30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0009-9236(98)90165-5","article-title":"Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole","volume":"63","author":"Neuvonen","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacl.2014.02.010_bib31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0009-9236(98)90023-6","article-title":"Effect of itraconazole on the pharmacokinetics of atorvastatin","volume":"64","author":"Kantola","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacl.2014.02.010_bib32","article-title":"2013 ACC\/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines [e-pub ahead of print]","author":"Stone","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2014.02.010_bib33","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2165\/00002018-200629050-00005","article-title":"Overcoming 'ageism' bias in the treatment of hypercholesterolaemia: a review of safety issues with statins in the elderly","volume":"29","author":"Jacobson","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.jacl.2014.02.010_bib34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.56.2.4","article-title":"Aging biology and geriatric clinical pharmacology","volume":"56","author":"McLean","year":"2004","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jacl.2014.02.010_bib35","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/ajcn\/81.5.953","article-title":"Aging muscle","volume":"81","author":"Nair","year":"2005","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jacl.2014.02.010_bib36","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.taap.2004.01.010","article-title":"The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes","volume":"199","author":"Parkinson","year":"2004","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.jacl.2014.02.010_bib37","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm204882.htm. Accessed February 9,\u00a02014."},{"key":"10.1016\/j.jacl.2014.02.010_bib38","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: interaction between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm293877.htm. Accessed February 9,\u00a02014."},{"key":"10.1016\/j.jacl.2014.02.010_bib39","unstructured":"US Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available at: http:\/\/aidsinfo.nih.gov\/guidelines#. Accessed November\u00a02013."},{"key":"10.1016\/j.jacl.2014.02.010_bib40","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/hep.510270121","article-title":"Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis","volume":"27","author":"Weltman","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jacl.2014.02.010_bib41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.5812\/hepatmon.5998","article-title":"Statins in the treatment of hepatitis C","volume":"12","author":"Vere","year":"2012","journal-title":"Hepat Mon"},{"key":"10.1016\/j.jacl.2014.02.010_bib42","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s11936-009-0028-2","article-title":"Use of statins in patients with liver disease","volume":"11","author":"Tandra","year":"2009","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.jacl.2014.02.010_bib43","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0002-9149(02)02355-X","article-title":"The liver and lovastatin","volume":"89","author":"Tolman","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2014.02.010_bib44","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/CIRCULATIONAHA.107.717777","article-title":"Statins and children: whom do we treat and when?","volume":"116","author":"Stein","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2014.02.010_bib45","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/apa.12280","article-title":"The safety of statins in children","volume":"102","author":"Lamaida","year":"2013","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.jacl.2014.02.010_bib46","unstructured":"National Kidney Foundation Inc. NFK KDOQI Guidelines. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Available at: http:\/\/www.kidney.org\/professionals\/kdoqi\/guideline_diabetes\/guide4.htm. Accessed February 9,\u00a02014."},{"key":"10.1016\/j.jacl.2014.02.010_bib47","unstructured":"Sandoz Canada I. Sandoz Lovastatin. Lovastatin Tablets USP Consumer Information. Available at: http:\/\/www.sandoz.ca\/cs\/groups\/public\/documents\/document\/n_prod_905330.pdf. Accessed February 9,\u00a02014."}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287414000725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287414000725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T19:49:09Z","timestamp":1565380149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287414000725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S1933287414000725"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2014.02.010","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}